Drugs / 18F-PBR06
18F-PBR06
also known as
Peripheral benzodiazepine receptor-06
Diagnostic / imaging agent targets TSPO
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03876002 | Jun 2016 → Feb 2018 | amyotrophic lateral sclerosis | Molecular NeuroImaging | Completed | No outcome recorded |
| Phase 1 | NCT01028209 | Nov 2009 → Sep 2010 | Alzheimer disease, Parkinson disease, multiple sclerosis | Institute for Neurodegenerative Disorders | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02513589 | Sep 2017 → Jul 2018 | ischemic stroke | University Hospital, Bordeaux | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]-PBR06 | “This study sought to assess the usefulness of the 18 kDa translocator protein (TSPO) tracers [11C]-PBR28 and [18F]-PBR06 for imaging inflammatory vascular disease in vitro and in vivo” PMID 33950298 ↗ May 2021 |
| Known as | Peripheral benzodiazepine receptor-06 | “To measure the dynamic uptake and washout of \[18F]PBR06 (Peripheral benzodiazepine receptor-06) in brain using positron emission tomography (PET) in patients with ALS and...” NCT03876002 ↗ |
| Modality | Diagnostic / imaging agent | “Two patients with carotid stenosis associated with ischemic stroke were imaged with [18F]-PBR06 PET/CT” PMID 33950298 ↗ May 2021 |
| Route | Intravenous | “injected intravenously as a bolus” NCT03876002 ↗ |
| Target | TSPO | “the 18 kDa translocator protein (TSPO) tracers [11C]-PBR28 and [18F]-PBR06 for imaging inflammatory vascular disease in vitro and in vivo” PMID 33950298 ↗ May 2021 |